Navigation Links
Tufts announces public launch of the Tufts Institute for Biomedical Partnerships website/HUB
Date:2/7/2011

BOSTON, MA (February 7, 2011) Tufts University today announced the public launch of the Tufts Institute for Biomedical Partnerships website/HUB: www.tuftspharmapartners.org

The Institute is university-wide, global pharmaceutical partnering initiative designed to create and manage a diverse portfolio of drug discovery and development partnerships.

The Institute was developed and is managed by Tufts University School of Medicine and Tufts University's Advancement Division.

"Our objective is to form innovative drug discovery and development alliances between Tufts and the pharma industry based on existing assets of strategic interest, while generating revenue streams to benefit the university and industry alike. To this end, we're focused on establishing a global brand for Tufts drug discovery and development expertise," said Lawrence J. Botticelli, Ph.D., Founder and current Chief Business Officer of the Institute.

The Institute's website is an interactive web medium, or "HUB", custom-developed and designed to educate and engage pharma partners, qualify partners and create distinctive alliances. The website functions as the Institute's principal commercialization portal, communication vehicle, strategic market resource, and information repository. It is designed to facilitate a distinctive approach to raising industry knowledge and awareness of Tufts' established expertise and the formation of important strategic alliances. Current information in the HUB includes five thematic areas of expertise derived from five different schools and one center. The site provides immediate access to nearly 60 research activities driven by more than 50 participating faculty members with navigable information in more than 300 categories.

"The creation of the HUB and the Tufts Institute for Biopharmaceutical Partnerships represents a landmark event and presents an exciting opportunity to those of us engaged in the discovery and innovation process," said Ira Herman, Ph.D., Professor and Director of the Program in Cellular and Molecular Physiology, Center for Innovations in Wound Healing Research at Tufts University School of Medicine. "We hope that this new portal will enable us to establish meaningful partnerships focused on delivering novel therapeutics and cutting edge technologies, as well as significantly extend current standards of care and clinical practice, locally and globally."

In his recent review of the website/HUB, David Damassa, Ph.D., Dean, Information Technology, Tufts University School of Medicine, commented, "The recently-published Institute for Biopharmaceutical Partnerships website, with its innovative Global Pharma Strategy & Project Development HUB, is a wonderful new resource benefitting both the global pharmaceutical industry and Tufts University. The design of the site and its theme areas of "Discover | Collaborate | Innovate" truly capture the unique culture of Tufts University Particularly compelling are the advanced search features of the HUB and its ability to create individual profiles so that use can be proactively connected with research and people of interest. The new site will undoubtedly raise industry knowledge and awareness of Tufts' established expertise and ability to form strategic alliances with industry, resulting in the development of important new drugs and technologies."

The Institute website/HUB introduces the pharma industry to a range of thematic areas of drug discovery and development expertise:

  • Innovative Therapies (Cancer, Infectious Disease, Cardiometabolic and Pulmonary Disorders, Neurological and Psychiatric Disorders),

  • Technology Platforms (Biomaterials and Biological scaffolding, Genetics, Genomics and Cell Function, Translational and Clinical Pharmacology, Functional Tissue Engineering, Functional Proteomic Screens)

  • Discovery & Development Services (Target Identification and Validation, Structural and Chemical Biology-Based Drug Design, Metabolic Analysis of Drug Candidates, In Vitro Models of Drug Transport, Experimental and Spontaneous Models of Disease),

  • Drug Development Science (Drug Disposition and Clinical Pharmacokinetics, Clinical Pharmacology, Drug Development and Regulation, Protocol Design and Complexity, New Models of Pharmaceutical Innovation, Pharmaceutical Economics)

  • Research Constellations (Establishment of non-traditional networks of robust research activities, including Regenerative Medicine, Biology and Aging, and Inflammation).

"The website/HUB is not simply an electronic repository of individuals, but a cogent, strategic expression of potential commercialization opportunities," said Dr Botticelli.

Researchers and companies interested in learning more about the University's drug discovery and development capabilities and how best to enter into a collaborative relationship with Tufts, can access information by navigating through the introductory "Institute" overview and learn about the Institute's focus, leadership, business model, and research, technology, and science, as well as research constellations that it represents. Upon entering the "HUB," users can obtain relevant information regarding therapeutic areas, technology platforms, discovery and development services, drug development science, and robust non-traditional research networks, including specific Tufts University practitioners engaged in such activities. Under "Faculty Member Profiles" detailed information on principal investigators can be obtained, including biosketches, areas of research interest, intellectual property estates, industry experiences, and relevant scientific publications.


'/>"/>

Contact: Christine Fennelly
617-636-3707
Tufts University, Health Sciences
Source:Eurekalert

Related biology news :

1. Tufts University Prof. Maria Flytzani-Stephanopoulos named as AAAS Fellow
2. Tufts University professor receives IADR Pharmacology/Therapeutics/Toxicology Award
3. Tufts students host Earth Day with groundbreaking ceremony for solar house
4. Tufts wins NCRR grant for Collaborative Cluster in Genome Structure and Developmental Patterning
5. Tufts graduate students win $10,000 prizes
6. Tufts University chemist earns prestigious award for promising research on drug development
7. Jackson Laboratory and Tufts University announce new Ph.D. track in mammalian genetics
8. NIAID announces 25 new awards to develop radiation countermeasures
9. Aware Announces Q3 2008 Earnings Conference Call
10. Governor Doyle announces historic genomic research collaboration
11. BIO-key(R) Announces Additional $245,000 in Third Quarter Public Safety Orders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2016)... Dec. 20, 2016  As part of its longstanding mission ... personal genetics company, recently released its latest children,s book, titled ... book focuses on the topics of inheritance and variation of ... (NGSS) taught in elementary school classrooms in the US. ... by illustrator Ariana Killoran , whose previous book with ...
(Date:12/16/2016)... 2016   IdentyTechSolutions America LLC , a ... solutions and a cutting-edge manufacturer of software and ... offering seamless, integrated solutions that comprise IDT biometric ... solutions provide IdentyTech,s customers with combined physical identification ... crime and theft. "We are proud ...
(Date:12/15/2016)... ... Markets has announced the addition of the "Global Military Biometrics Market ... the global military biometrics market to grow at a CAGR of 7.5% ... based on an in-depth market analysis with inputs from industry experts. The ... years. The report also includes a discussion of the key vendors operating ...
Breaking Biology News(10 mins):
(Date:1/18/2017)... ... January 18, 2017 , ... DrugDev ... Summit for Clinical Ops Executives (Hyatt Regency Miami, January 24-26). DrugDev will join ... clinical research issues such as trial performance metrics, patient enrollment diversity, protocol optimization, ...
(Date:1/18/2017)... -- HUYA Bioscience International, (HUYA), the leader in accelerating the ... innovations, announced today a strategic collaboration agreement with the ... to as CAS Innovation). The collaboration will focus on ... at CAS to meet the medical needs of patients ... company to have recognized China,s ...
(Date:1/17/2017)... ... 17, 2017 , ... MS Technologies™ and Bayer have received ... Performance System will combine industry-leading genetics with a double herbicide-tolerant trait that will ... Bean herbicide. The Balance™ GT Soybean Performance System will benefit soybean growers by ...
(Date:1/17/2017)... , Jan. 17, 2017   Pulmatrix, Inc . ... company developing innovative inhaled therapies to address serious pulmonary ... fungal infections in the lungs of CF patients, PUR1900, ... (QIDP) by the U.S. Food & Drug Administration. ... designed to speed the development of novel drugs against ...
Breaking Biology Technology: